Welcome to BeiMedPlus

BeiGene's medical website with resources for healthcare professionals and disease information for patients and caregivers.

Please confirm the option below that best describes you so we can direct you to appropriate resources and information.

I am a...

Healthcare Professional

hcp

Patient / Caregiver

patient

BeiGene Employee

employee

I am from...

Germany / DE

Switzerland / DE

ch-de

Switzerland / FR

ch-fr

Switzerland / IT

ch-it

United States / EN

France / FR

Spain / ES

Sweden / SE

Italy / IT

Europe / EN

pts-en

Europe / EN

Select Your Location:

Global

Resource Center
- Congresses and Events
Development Program
Contact Us

Choose Language

English

Solid Tumors

BeiGene is advancing a solid tumor pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. Among these are tislelizumab, a monoclonal antibody against PD-1 and ociperlimap, a monoclonal antibody against TIGIT.

All Types

Reading

Slide-Kit

Video

Latest

latest

Oldest

oldest

All Types

Reading

Slide-Kit

Video

Latest

latest

Oldest

oldest

Suggested:

CLL

EHA

ESMO

Hematologic Malignancies

Solid Tumors

Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

Video

29 May 2024

Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Video

29 May 2024

This website is intended for US Healthcare Professionals for scientific information exchange purposes only, not for advertising purposes, and does not constitute commercial promotion of any product or recommendation on diagnosis and treatments.The website may contain information about products or indications that have not yet been approved in your country; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

The safety and efficacy of investigational products or uses may not have been established. Because of the uncertainty of clinical trials, there is no guarantee that compounds will receive regulatory approval and become commercially available for the uses being investigated.

REPORT AN ADVERSE EVENT

adverse_event@beigene.com
Contact Us by Phone

REPORT A PRODUCT COMPLAINT

productscomplaints@beigene.com
Contact Us by Phone

CONTACT US

beigene.com/contact-us
Contact Us by Phone

About Us
Privacy Policy
Terms of Use

memo inOncology

OncologyPro

You're now leaving the website www.beimedplus.com

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave www.beimedplus.com website. The link will take you to another BeiGene website, the content of which is subject to the locally applicable laws and regulations.

BeiGene Ltd. makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, I want to go back Yes, I would like to continue

You're now leaving the website www.beimedplus.com

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave www.beimedplus.com website. The link will take you to a website owned and operated by an independent party over which BeiGene Ltd. has no control or influence (“third-party website”).

BeiGene Ltd. makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene Ltd. declines any responsibility for third-party information. BeiGene Ltd. makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the target group of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.

Do you really want to leave the www.beimedplus.com website?

No, I want to go back Yes, I would like to continue